Metsera had its Relative Strength (RS) Rating upgraded from 78 to 85 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.
While it's not currently an ideal time to jump in, see if the stock manages to form a chart pattern and break out.
Metsera showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
Metsera holds the No. 296 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
